COMMUNIQUÉS West-GlobeNewswire

Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy
06/05/2025
Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study ( NCT06769048 ), investigating the efficacy and safety of BI 1584862 as a potential first-in-class [...]
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
06/05/2025
Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a [...]
IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology
06/05/2025
Data from OVATION 2 trial will also be reviewed in an oral presentation at ASCO Annual Meeting on June 3, 2025 LAWRENCEVILLE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage [...]
Candel Therapeutics to Present at Upcoming Investor Conferences
06/05/2025
NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
FOXO TECHNOLOGIES INC.’S BEHAVIORAL HEALTH SUBSIDIARY REACHES KEY OPERATIONAL MILESTONES
06/05/2025
WEST PALM BEACH, FLORIDA, May 06, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “ Company ”) today announced that its behavioral health subsidiary, Myrtle Recovery Centers, Inc., [...]
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
06/05/2025
If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and additionally the istaroxime U.S. issued method of use patent protects until 2039 for its planned [...]
Nova Leap Health Corp. announces Closing of Home Care Acquisition in Nova Scotia
06/05/2025
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, May 06, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) ("Nova Leap" or “the Company”), a [...]
Sofwave Medical Reports First Quarter Fiscal 2025 Financial Results and Business Highlights
06/05/2025
— First quarter revenue of $1 6.7 M, +2 6 % year-over-year growth; IFRS gross margin of 7 6.3 % — First quarter pulse recurring revenue of $ 7.0 M , + 49 % year-over-year growth — IFRS and non-IFRS operating loss of -$ [...]
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases
06/05/2025
Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing [...]
Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion
06/05/2025
Arabic, Italian, and Spanish-language websites unlock commercial access to regions representing over 1.4 billion people Multilingual rollout aligns with product readiness and accelerates international sales pipeline [...]
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
06/05/2025
Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage [...]
Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025
06/05/2025
SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization [...]
Viemed Executes Diversification Strategy With $26 Million Acquisition of Home Equipment Provider in Illinois
06/05/2025
LAFAYETTE, La., May 06, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ: VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the [...]
Alpha Tau to Participate in May Investor Conferences
06/05/2025
JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced [...]
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
06/05/2025
VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple [...]
Digital Utilities Ventures CEO Mark Gaalswyk Meets with QFFD in Qatar
06/05/2025
Easy Environmental Solutions, Inc. Enters Strategic Talks with QFFD and African Governments to Accelerate a New Era of Regenerative Agriculture and Clean Water Infrastructure Strategic Partnership with QFFD to Transform [...]
SRx Health Solutions to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
06/05/2025
TAMPA, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced it will host a conference call and webcast on [...]
Imprivata Wins Global InfoSec Awards in Passwordless Authentication and Third Party Risk Categories
06/05/2025
WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Imprivata , the digital identity company for life- and mission-critical industries, today announced that the company has won two Global InfoSec Awards 2025 , presented by [...]
Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)
06/05/2025
Dr. Hasskarl to lead global Phase 3 MO-TRANS study evaluating mocravimod as an adjunctive treatment to allo-HCT in AML Saint-Louis, France and Dublin, Ireland – 6 th May 2025 – Priothera Ltd., a late-stage biopharma [...]

Pages